Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
AP
Apnimed Inc APMD
$21.09
▼ -2.50%
($-0.54)
Open
$22.00
Prev Close
$21.63
Day Range
$20.68 – $22.77
52W Range
$16.12 – $35.29
Market Cap
$877.99M
Beta
3.35
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| IPO Date | 2026-07-31 |
| Website | apnimed.com ↗ |
| Phone | 18772764633 |
| Shares Out. | 41,630,779 |
About Apnimed Inc
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
Apnimed Inc is a publicly traded company under the ticker symbol APMD on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.